Clinical Research Directory
Browse clinical research sites, groups, and studies.
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
Sponsor: Oregon Health and Science University
Summary
This is a single center prospective study evaluating 124I-evuzumitide in patients with systemic amyloidosis. The purpose of this study is to 1)identify and characterize the distribution and uptake of 124I-evuzumitide in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and 2) Correlate the uptake with the structure and function of different organs, including the heart. To achieve these goals, eligible patients will undergo primarily hybrid positron emission tomography and magnetic resonance imaging (PET/MRI). In a subgroup of patients who are unable to undergo PET/MR, computed tomography will be used instead of MRI (i.e. PET/CT). In a subgroup of patients, repeat imaging with the same modality will be done at a interval of 6-12 months. Clinically available data (demographics, phenotype, imaging, laboratory) will also be collected to characterize the disease in each patient.
Key Details
Gender
All
Age Range
18 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2023-01-10
Completion Date
2028-03-10
Last Updated
2025-12-22
Healthy Volunteers
No
Conditions
Interventions
124I-Evuzamitide
Amyloid reactive protein used as imaging agent to detect systemic amyloidosis
Locations (1)
Oregon Health & Science University
Portland, Oregon, United States